医院为基础的卵巢癌患者追溯项目遗传检测接受率极低
本研究评估医院为基础对卵巢癌患者进行遗传咨询与检测(GC/T)追溯的可行性。2006至2016年共识别598例符合追溯条件的卵巢癌患者(推定在世163例,已故435例)。通过信件联系在世患者、电话联系已故患者代理人,最终仅14人接受遗传咨询、10人同意检测、5人完成采样,无人检出致病性变异。结论认为该追溯方式耗时且GC/T接受率极低。
要点
- 医院为基础的信件和电话代理人追溯方式耗时109小时,GC/T接受率极低。
- 598例符合追溯条件患者中,最终仅5人完成样本采集,均未检出致病性变异。
- 代理人电话联系中58%记录为积极回应,42%为消极或冷淡回应,后者多见于配偶。
核心结论
- 医院为基础通过信件和电话联系代理人的追溯方式耗时且GC/T接受率极低。
- 为实际执行此类外展项目,卫生系统应考虑收集替代联系方式以便与患者代理人进行电子沟通。
- 本研究强调在患者处于积极癌症治疗期间及时进行GC/T的重要性。
研究设计与样本
- 研究评估医院为基础对卵巢癌患者进行遗传咨询与检测追溯的可行性,追溯方案由美国国家癌症研究所癌症预防部和癌症控制与人口科学部提出。
- 向在世卵巢癌患者寄送信件说明指南支持的至少BRCA1/2遗传咨询与检测的可及性,对已故患者的代理人进行电话联系。
- 系统记录联系尝试结果并进行统计描述。
主要发现
- 2006至2016年共识别598例符合追溯条件的卵巢癌患者,其中推定在世163例,已故435例。
- 2例在世患者在收到信件后致电办公室并预约遗传咨询与检测。
- 对既往患者代理人的电话联系中,25%的呼叫尝试成功联系。
- 14人(2例在世患者和12名代理人)接受了遗传咨询,其中10人同意遗传检测,5人完成样本采集,这些个体均无致病性变异。
- 回顾代理人电话记录,58%反映对联系为积极回应,42%记录为消极或冷淡回应,后者在配偶中最常见;医院为基础追溯总耗时109小时。
临床怎么用
- 作者认为,为实际执行此类外展项目,卫生系统应考虑收集替代联系方式以便与患者代理人进行电子沟通。
- 作者强调在患者处于积极癌症治疗期间及时进行遗传咨询与检测的重要性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the feasibility of hospital-based genetic counseling and testing (GC/T) Traceback for Ovarian Cancer (OC) patients, as proposed by the Division of Cancer Prevention and the Division of Cancer Control and Population Sciences, National Cancer Institute. METHODS: Living patients with OC were sent a letter explaining the availability of guideline-supported GC/T for at least BRCA1/2 and surrogates of deceased patients were called on the telephone. Outcomes of contact attempts were systematically recorded and statistically described. RESULTS: 598 Traceback-eligible OC patients diagnosed from 2006 to 2016 were identified (163 presumed-living and 435 deceased). Two living patients called our office and scheduled an appointment for GC/T after receiving a letter. For surrogates of prior patients, successful contact occurred in 25% of call attempts. Fourteen individuals (2 living patients and 12 surrogates) underwent genetic counseling. Of those 14, 10 individuals consented to genetic testing and 5 followed through with sample collection. None of these individuals had pathogenic variants (PVs). When surrogate call notes were reviewed, 58% reflected positive responses to contact, however 42% were noted to have negative or indifferent responses, which were most common among spouses. Total time spent for hospital-based Traceback was 109 h. CONCLUSIONS: Overall, hospital-based Traceback via letter and telephone contact of surrogates is time-intensive and results in minimal uptake of GC/T. To practically execute this type of outreach program, health systems should consider collection of alternative contact information to allow for electronic communication of patient surrogates. Our study also underscores the importance of timely GC/T while patients are in active cancer care.
引用
- Weinmann S, Phillips S, Sweet K, et al. Hospital-based ovarian cancer patient traceback program results in minimal genetic testing uptake. Gynecol Oncol. 2022. PMID: 34998598. doi:10.1016/j.ygyno.2021.12.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。